Ms. magazine  -- more than a magazine a movement

SIGN UP FOR MS. DIGEST, JOBS, NEWS AND ALERTS

FEMINIST WIRE NEWSBRIEFS

ABOUT
SEE CURRENT ISSUE
SHOP MS. STORE
MS. IN THE CLASSROOM
FEMINIST DAILY WIRE
FEMINIST RESOURCES
PRESS
JOBS AT MS.
READ BACK ISSUES
CONTACT
RSS (XML)
 
feminist wire | daily newsbriefs

August-16-10

FDA Approves 5-Day Emergency Contraceptive

The Food and Drug Administration (FDA) has approved a new emergency contraceptive, Ella or ulipristal acetate, which is effective at preventing pregnancy up to five days after contraceptive failure or unprotected sexual intercourse. In June, a panel of FDA expert medical advisors unanimously agreed that it is safe and effective in preventing the release of an egg. The drug inhibits or delays ovulation by diminishing the effects of progesterone, according to theFDA release.

Ella will be available by prescription only, according to the Los Angeles Times.

According to the New York Times, Ella is more effective than Plan B, the "morning-after" pill available over the counter to women over the age of 17 in the United States. Plan B is only effective three days after contraceptive failure or unprotected sex. Side effects of Ella are similar to those of Plan B, including headache, nausea, abdominal pain, pain/discomfort during menstruation (dysmenorrhea), fatigue, and dizziness, according to WebMD Health News.

The drug, under the name EllaOne, is made by French company HRA Pharma. It is available with a prescription in Europe and is currently approved in 22 countries. Watson Pharmaceuticals Inc. will distribute Ella in the United States.

Anti-choice advocates argue that EllaOne is akin to mifepristone, which terminates existing pregnancies. According to Reuters, supporters of EllaOne agree that the drug is chemically similar to mifepristone, but one dose will not interfere with existing pregnancies. "There's just no evidence that it causes abortion," said Dr. Paul Fine, a Baylor College of Medicine professor and the medical director for Planned Parenthood in Houston and Southeast Texas.

Planned Parenthood has commended the FDA's decision. Planned Parenthood President Cecile Richards said, "Every woman deserves every option available to prevent an unplanned pregnancy, and there are many reasons why a woman may face the risk of unintended pregnancy, from failure or improper use of birth control to sexual assault," in a statement. "The FDA's approval of this new form of emergency contraception gives women one more option."

Media Resources: FDA Release; Feminist Newswire 6/16/10, 6/18/10; Los Angeles Times 8/13/10; New York Times 8/13/10; WebMD Health News 8/13/10; Planned Parenthood Press Release 8/13/10; Reuters 6/15/10


© Feminist Majority Foundation, publisher of Ms. magazine

If you liked this story, consider making a tax-deductible donation to support Ms. magazine.

 

 

Send to a Friend
Their
Your
Comments
(optional)


More Feminist News

8/26/2014 More Investment in Women's Health Needed as Africa's Population Rises - Africa's population will reach four billion by 2100, according to a report released by UNICEF early this week. . . .
 
8/26/2014 92 Million Dollar Project Will Improve Higher Education in Afghanistan - The US Agency for International Development (USAID) announced a $92 million project to improve the higher education system in Afghanistan last week. The University Support and Workforce Development Project (USWDP) represents a five-year plan between USAID and the Afghan Ministry of Higher Education (MoHE) and Ministry of Economy to improve Afghanistan's educational programs according to international standards. . . .
 
8/25/2014 Advocates Seek to Block Louisiana TRAP Law in Federal Suit - Friday, the Center for Reproductive Rights joined a federal lawsuit challenging a Louisiana TRAP (Targeted Regulation of Abortion Providers) law set to take effect September 1. The suit, filed on behalf of health care workers in Baton Rouge, seeks an injunction against Louisiana HB 388, which requires abortion providers in the state to obtain local hospital admitting privileges. . . .